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Abstract
Background: Due to the restrictive nature of a gluten-free diet, celiac patients are looking for alternative therapies.
While drug-development programs include gluten challenges, knowledge regarding the duration of gluten
challenge and gluten dosage is insufficient.
We challenged adult celiac patients with gluten with a view to assessing the amount needed to cause some small-
bowel mucosal deterioration.
Methods: Twenty-five celiac disease adults were challenged with low (1-3 g) or moderate (3-5g) doses of gluten
daily for 12 weeks. Symptoms, small-bowel morphology, densities of CD3+ intraepithelial lymphocytes (IELs) and
celiac serology were determined.
Results: Both moderate and low amounts of gluten induced small-bowel morphological damage in 67% of celiac
patients. Moderate gluten doses also triggered mucosal inflammation and more gastrointestinal symptoms leading
to premature withdrawals in seven cases. In 22% of those who developed significant small- intestinal damage,
symptoms remained absent. Celiac antibodies seroconverted in 43% of the patients.
Conclusions: Low amounts of gluten can also cause significant mucosal deterioration in the majority of the
patients. As there are always some celiac disease patients who will not respond within these conditions, sample
sizes must be sufficiently large to attain to statistical power in analysis.
Background
Celiac disease is an autoimmune-like systemic disorder in
genetically susceptible individuals, perpetuated by daily
ingested gluten cereals wheat, rye and barley and with
manifestations in the small- intestinal mucosa and in
organs outside the gut. The gold standard for celiac dis-
ease diagnosis is the finding of gluten-induced small-
intestinal mucosal injury [1,2]. The mucosa will heal
upon introduction of a gluten-free diet and the mucosal
damage will reappear if gluten is reintroduced [2]. Exten-
sive time-course studies have provided evidence that dur-
ing gluten challenge an inflammatory process with a
dose-dependent accumulation of intraepithelial lympho-
cytes (IELs) is followed by mucosal villous atrophy with
crypt hyperplasia [3]. In untreated celiac disease the
degree of malabsorption is determined by the length of
the functionally impaired bowel and the presence of
symptoms is noway related to the histological features of
a proximal biopsy [3-5]. More recently, it was concluded
that only patients with extensive and severe enteropathy
will give evidence of steatorrhea and increased intestinal
permeability[6]. Biopsy has thus remained the golden
standard in measuring gluten-induced ill health.
Previously a gluten challenge was part of the routine
diagnostic procedure in children and a characteristic
mucosal lesion reappeared in most patients within two
years[2,7]. In gluten challenge studies, the amount of
gluten in normal food has been estimated to be as high
as 10-20 g per day[8-10]. A reduced daily gluten dose
(2.5-5 g per day) during a gluten-free diet has still
enabled mucosal healing in half of the patients [11].
Also some adults challenged with 2.5-5 g of gluten daily
for three to 14 months have shown no significant
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in marked conflict with those from a recent challenge
study where it was shown that even a minimal dose of
50 mg gluten daily induced a significant mucosal dete-
rioration [13]. Altogether, the patient groups in these
studies have been rather small and no unequivocal con-
clusions can be drawn.
A gluten-free diet is socially troublesome and expensive
and research has shown compliance to the diet often to be
poor [14]. Gluten contamination in a gluten-free diet is
also difficult to avoid [15,16]. For these reasons many
celiac patients have expressed a desire for other alternative
or complementary treatments, less burdensome than a
strict life-long gluten-free diet [17,18]. Any drug under
evaluation as clinically effective and trusted by celiac dis-
ease patients should significantly reduce or prevent glu-
ten-induced mucosal injury. However, data are insufficient
as to the amount of gluten to be used in a challenge study
and for how long.
In this pilot study we challenged adult celiac disease
patients with gluten aiming to gain a clearer conception of
the gluten amount needed to cause some mucosal dete-
rioration but without inducing excessive ill health with a
resultant dropout of trial subjects. We challenged treated
celiac disease patients with low to moderate amounts of
gluten for up to 12 weeks to establish whether a morpho-
metrically measurable mucosal deterioration could be
detected. We especially measured separately mucosal mor-
phological change as villous height crypt depth ratio (Vh/
CrD) and the inflammatory aspect in terms of density of
mucosal IELs, both known to be sensitive continuous
functional parameters of gluten ingestion in celiac disease.
Further, we sought to establish whether the gluten-depen-
dent serum antibody markers show seroconversions.
Methods
Patients and study design
Altogether 25 adult volunteers with previously diagnosed
celiac disease were recruited for the gluten challenge
study. Inclusion criteria comprised biopsy-proven celiac
disease in patients aged 18-75 years adhering to a strict
gluten-free diet for at least two years and being in clinical
remission as judged by an interview, clinical examination
and on-site rapid celiac autoantibody testing. Patients with
a history of regular dietary transgressions, and those suf-
fering from a condition carrying a risk at endoscopy, or
using immunosuppressive medication were excluded.
At the outset the symptoms or signs leading to the
diagnosis of celiac disease, the duration of the gluten-free
diet, family history of celiac disease and associated condi-
tions were recorded. Upper gastrointestinal endoscopy
with duodenal biopsies, laboratory analysis and clinical
evaluation including gastrointestinal symptoms, were car-
ried out at baseline and after the challenge. The complete
challenge lasted 12 weeks (84 ± 14 days). Furthermore, at
4 weeks (28 ± 7 days) and 8 weeks (56 ± 14 days) the
clinical and serological assessments were repeated. The
study patients were divided into two groups, those con-
suming a moderate (3-5 g) amount of gluten and those
consuming a low (1-3 g) amount of gluten daily. Those
who prematurely withdrew from the study were encour-
aged to undergo follow-up examinations immediately
after the challenge was discontinued. After the challenge
all patients continued their normal gluten-free diet.
Gluten product and dietary assessment
Each patient consumed 1.25-5 g of gluten (as a biscuit)
daily during the challenge while otherwise continuing on a
strict gluten-free diet. A verified amount of industrial glu-
ten (Meelunie, Amsterdam, the Netherlands) was added to
the baking mixture of the biscuits, and the mean daily glu-
ten consumption of each patient was calculated. Con-
sumption of the gluten product, changes in dietary habits
and possible dietary transgressions were inquired at each
visit and by regular telephone contacts. At baseline and at
the end of the study a dietitian made a detailed dietary
analysis by means of interview and a 4-day record of food
intake.
Small-bowel mucosal morphology and inflammation
Up to seven small-bowel biopsy specimens were taken
from the distal part of the duodenum upon upper gastro-
intestinal endoscopy; the specimens were evaluated by the
same investigator without prior knowledge of the history
or findings. At least three biopsies were processed and
stained with hematoxylin-eosin and studied under light
microscopy. Poorly oriented sections were discarded;
when necessary, the samples were dissected repeatedly
until they were of good quality. Morphometric analysis
measuring Vh/CrD was made in well-oriented biopsy sam-
ples as previously described [19], and a ratio < 2.0 was
regarded as compatible with villous atrophy and crypt
hyperplasia and indicative of active celiac disease. During
the gluten-challenge, a decrease in Vh/CrD of 0.5 or more
was considered significant and equivalent to clinical
glutensensitivity [20].
The remaining biopsies were snap-frozen for immuno-
histochemical stainings. The specimens were freshly
embedded in optimal temperature compound (OCT,
T i s s u e - T e c ,M i l e sI n c ,E l k h a r t ,I N ,U S A ) ,s n a p - f r o z e ni n
liquid nitrogen and stored at -70°C. Immunohistochemical
studies were carried out on 5-μm-thick frozen sections.
CD3+ IELs were stained with monoclonal antibody Leu-4
(Becton Dickinson, San Jose, CA, USA). IELs were
counted with a x100 flat-field light microscope objective
in randomly selected surface epithelium and the density of
IELs expressed as cells/millimetre of epithelium as pre-
viously described, the reference values being set at
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lenge an over 30% increase in IEL counts was considered
significant and equivalent to clinical glutensensitivity [20].
In our laboratory the correlation coefficients for intraob-
server variation for CD3+ IELs has been 0.95 and that for
interobserver variation 0.92.
Celiac serology
Serum IgA class transglutaminase 2 (TG2)-antibodies
were investigated by an enzyme-linked immunosorbent
assay (ELISA) according to manufacturer’s instructions
(QUANTA Lite h-tTGIgA, INOVA, Diagnostics, Inc,
CA, USA). The cut-off value for a positive antibody level
was 20 IU. Serum IgA class endomysial antibodies
(EMA) were determined by an indirect immunofluores-
cence method using human umbilical cord as substrate; a
dilution of 1:5 or more was considered positive [22].
Positive sera were further diluted: 1:50, 1:100, 1:200,
1:500, 1:1000, 1:2000, 1:4000. We also determined a com-
bination of serum IgA and IgG class deaminated gliadin
peptide (DGP) antibodies (QUANTA Lite Celiac DPG
Screen, INOVA Diagnostics) by ELISA, and values ≥20
IU were considered positive. None of the study subjects
suffered from selective IgA deficiency. The change in
antibody levels was considered clinically significant when
antibodies seroconverted from negative to positive or
when positive antibody levels increased and at least
doubled during the gluten challenge.
Small-bowel mucosal TG2-targeted autoantibody deposits
The small bowel mucosal TG2- specific autoantibody
deposits were studied by direct immunofluorescence
methods in frozen biopsy sections [20,23-25]. From each
patient altogether six unfixed, 5-μm-thick sections from
frozen small-bowel specimens were processed, three for
investigation of IgA deposits and three for double-color
labelling for both IgA and TG2. IgA was detected by
direct immunofluorescence using fluorescein isothiocya-
nate-labelled rabbit antibody against human IgA (Dako
AS, Glostrup, Denmark) as previously described [23]. In
celiac disease a clear subepithelial IgA deposition was
found below the basement membrane along the villous
and crypt epithelium and around mucosal vessels, in con-
trast to that observed in non-celiac samples, where only
endogenous IgA is found inside plasma cells and epithe-
lial cells. Sections were further double-stained for human
IgA (green, as above) and for TG2 (red, monoclonal
m o u s ea n t i b o d yC U B 7 4 0 2 ,N e o M A r e r s ,F r e m o n t ,C A ,
USA, followed by rhodamine-conjugated anti-mouse
immunoglobulin antibodies, Dako) to confirm that
celiac-type IgA deposits co-localized with TG2. The
occurrence of IgA deposits was graded semi-quantita-
tively according to their intensity along the basement
membrane in the villous-crypt area as follows: negative
(0), weak (+), moderate (++) and strong positive (+++).
In cases where the intensity of the staining was patchy, it
was graded from different areas and the mean value was
given. All evaluations were carried out in blinded fashion
without knowledge of disease history or laboratory find-
ings. The correlation coefficients for both intraobserver
and interobserver variations for the detection of presence
or absence of TG2-specific IgA deposits have been 0.98
in our laboratory. An increase in the intensity of IgA-
deposit staining after gluten challenge was considered
indicative of clinical gluten-sensitivity.
Gastrointestinal symptoms
Clinical symptoms appearing during the gluten challenge
were semiquantatively classified into four categories- no
symptoms, slight, moderate or severe symptoms- by
means of interview and recorded at each visit.
Statistics
Quantitative data were expressed as medians and ranges
or means and 95% confidence intervals (CI). Statistical
differences were evaluated using Mann-Whitney test
and Wilcoxon’s test or unpaired and paired t-test as
appropriate, and all testing was two-sided. Fisher’s exact
test was used in cross-tabulations. The Pearson coeffi-
cient was used for correlation studies. P-values < 0.05
were considered statistically significant. All statistical
testing was performed using SPSS version 16.0 (SPSS
Inc., Chicago, IL, USA)
Ethical considerations
The study protocol was approved by the Ethics Com-
mittee of Tampere University Hospital. All subjects gave
written informed consent.
Results
Altogether 25 adult celiac disease patients fulfilling the
inclusion criteria were enrolled for the study (Table 1). At
the time of the diagnosis, the majority (88%) had suffered
from abdominal symptoms. When volunteering for this
study, the patients had been a median of 11 years on a
strict gluten-free diet, and all were in clinical remission.
At baseline in the current study, all patients except one
had normal Vh/CrD ratios (median 2.9, range 1.3-4.2) on
small-intestinal biopsy (Table 2). The mean density of
CD3+ IELs was 63 cells/mm (range 23-146). Altogether
six patients had borderline positive celiac disease anti-
body levels (three had positive TG2 antibodies, two EMA
and one DGP antibodies); in the rest all three antibodies
were negative. When TG2-targeted autoantibodies were
assessed at small-bowel mucosal level, moderate IgA-
deposits were seen in two and faint in four patients. In
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depositions were negative at the beginning of the chal-
lenge study.
Altogether four celiac disease patients belonging to the
moderate gluten dose group discontinued the study due
to abdominal symptoms shortly after the challenge was
initiated (after three, eight, ten and 23 days), and they
were excluded from the final analyses. Celiac serology
remained negative in all. The first two drop-outs with
extremely brief gluten challenges underwent the follow-
up endoscopy, and no small- bowel mucosal deteriora-
tion was evident.
The remaining 21 patients comprised the final study
population (Tables 2 and 3), for whom the gluten chal-
lenge lasted a median of 84 days (range 29-103 days)
Table 1 Demographic data on the 25 celiac disease
patients
Variable
Female; n 21 (81%)
Age; median (range), years 49 (21-68)
Reason for suspicion of celiac disease at diagnosis
Abdominal symptoms 23 (88%)
Anemia or malabsorption 16 (62%)
Extraintestinal manifestations* 9 (35%)
Screening in risk groups of celiac disease† 1 (4%)
Duration of gluten free diet; median (range), years 11 (2-34)
Family history of celiac disease, n 8 (31%)
*tooth enamel hypoplasia, hypothyreosis, growth delay
† family history of celiac disease
Table 2 Effect of moderate (3-5g) and low (1-3g) amounts of gluten on small-bowel mucosal villous height crypt
depth ratio (Vh/CrD), densities of CD3+ intraepithelial lymphocytes (IELs) and gastrointestinal symptoms in treated
celiac disease patients
No Mean daily gluten intake (g) Duration of gluten challenge (days) Small-bowel biopsy Symptoms‡
Vh/CrD* CD3+ IELs†
I II I II I II
Moderate amounts of gluten daily
1 5.0 29 2.8 0.8 33 88 0 ++
2 4.9 84 3.5 3.4 43 84 00
3 4.9 38 2.9 1.3 64 128 0 ++
4 4.7 45 2.7 0.2 70 113 0 +
5 4.1 61 3.0 3.5 41 56 0 ++
6 4.0 91 3.0 0.6 45 97 0 +
7 3.6 91 2.8 1.4 42 125 00
8 3.6 84 3.0 2.6 38 47 0 +
9 3.4 88 3.8 2.3 69 83 0 +
10 3.3 86 2.7 0.6 68 96 0 +
Low amounts of gluten daily
11 2.8 89 2.5 3.1 87 52 0 +
12 2.7 84 3.0 0.6 87 117 00
13 2.6 81 2.9 3.1 49 50 0 0
14 2.4 85 2.7 1.9 146 271 0 +
15 2.2 103 4.2 1.3 23 48 0 +
16 2.1 93 1.3 0.1 130 99 0 +
17 2.1 85 3.3 2.4 100 79 0 +
18 2.1 84 2.9 1.7 75 78 0 0
19 2.1 83 3.2 3.4 70 123 0 +
20 1.4 77 3.4 3.0 41 87 0 ++
21 1.3 78 2.5 0.8 53 71 00
Altogether positive outcome§, n (%) 14 (67%) 14 (67%) 15 (71%)
Clinically significant changes between baseline (I) and 12 weeks’ follow-up examination (II) are marked in bold numbers. Complete challenge lasted 12 weeks (84
± 14 days).
* Abnormal ratio compatible with active celiac disease <2.0
† Reference value for CD3+ IELs 37 cell/mm
‡ Symptoms graded as 0 = no symptoms, + = mild symptoms, ++ = moderate symptoms,
§ Positive outcome reported when clinically significant changes appeared (>0.5 decrease in Vh/CrD, >30% increase in IEL densities) or when symptoms
worsened.
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(range 1.3-5.0 g/day). When the cohort was further
divided according to the average daily gluten intake, ten
patients belonged to the moderate-dose (3-5 g) and 11
to the low-dose (1-3 g) gluten challenge group (Tables 2
and 3). In the moderate-dose group, three patients with-
drew prematurely (after 29, 38 and 61 days) by reason
of abdominal symptoms such as diarrhea, vomiting and
abdominal pain; one patient discontinued at day 45 for
personal reasons. Intended end-point examinations were
carried out in all four cases immediately after cessation
of the challenge. All celiac patients in the low-dose glu-
ten challenge group completed the study as planned
after 12 weeks’ challenge. Patients with a moderate glu-
t e nd o s ew e r et h u sm o r ep r o n et h a nt h o s ew i t hal o w
dose to withdraw prematurely from the study (p =
0.035).
During the gluten challenge, a clinically significant
decrease in Vh/CrD was found in 14 (67%) out of the 21
celiac patients; seven were in the moderate and seven in
the low gluten dose group (Table 2, Figures 1 and 2). The
Vh/CrD in the moderate-dose group deteriorated from a
mean 3.0 (95%CI 2.8-3.2) to 1.7 (95%CI 1.0-2.4) and in
the low-dose group from 2.9 (95%CI 2.5-3.4) to 1.9 (95%
CI 1.2-2.6), both changes being statistically significant (p
= 0.002 and p = 0.016, respectively). The changes in Vh/
CrD did not correlate with daily gluten intake (r = -0.138,
p = 0.552).
In line with the morphological findings, a clinically sig-
nificant change in the density of CD3+ IELs was seen in
altogether 14 (67%) subjects; eight in the moderate-dose
and six in the low-dose of (Table 2, Figures 3 and 4). In
t h em o d e r a t eg l u t e nd o s eg r o u pt h eI E Lc o u n ti n c r e a s e d
significantly from a mean 49 cell/mm (95%CI 38-60) to
88 cell/mm (95%CI 70-106, p = 0.001). In the low-dose
group the increase did not reach statistical significance
(from a mean 78 cell/mm [95%CI 56-100] to 98 cell/mm
[95%CI 61-135], p = 0.188). All in all, daily gluten intake
did not correlate with increased inflammation (gluten
intake vs. ΔCD3+ IEL count, r = 0.251, p = 0.273).
Table 3 Effect of moderate (3-5g) and low (1-3g) amounts of gluten on serum transglutaminase 2 (TG2) antibodies
and small bowel mucosal TG2-targeted autoantibody deposits in treated celiac disease patients
No Mean daily gluten intake Duration of gluten Serum TG2 antibodies* Mucosal TG2 antibody deposits†
II I I I I
Moderate amounts of gluten daily
1 5.0 29 10 319 0 +++
2 4.9 84 9 13 0 0
3 4.9 38 5 10 0 +
4 4.7 45 44 218 + +++
5 4.1 61 6 5 0 0
6 4.0 91 21 263 + +++
7 3.6 91 6 47 0 ++
8 3.6 84 8 10 ++ +
9 3.4 88 13 16 0 0
10 3.3 86 18 229 + +++
Low amounts of gluten daily
11 2.8 89 6 7 0 ++
12 2.7 84 7 111 0 ++
13 2.6 81 7 5 0 0
14 2.4 85 12 88 0 ++
15 2.2 103 9 9 0 0
16 2.1 93 16 94 ++ ++
17 2.1 85 9 8 0 0
18 2.1 84 24 21 + +
19 2.1 83 8 8 0 0
20 1.4 77 10 13 0 +
21 1.3 78 14 101 0 ++
Altogether positive outcome‡, n (%) 9 (43%) 11 (52%)
Clinically significant changes between baseline (I) and 12 weeks’ follow-up examination (II) are marked in bold letters. Complete challenge lasted 12 weeks (84 ±
14 days).
* Values of ≥20 IU considered positive
† Graded as negative (0), weak (+), moderate (++) and strong positive (+++)
‡ Positive outcome reported when serum antibody levels or intensity of mucosal autoantibody deposits increased.
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moderate- and four in the low-dose gluten challenge
group, showed significant increases in TG2 antibody titers
(Table 3). The subjects consuming moderate doses of glu-
ten evinced clearly higher TG2 antibody titer responses
than those consuming low doses; this was already seen
after four weeks’ challenge (Figure 5). Interestingly, after
the highest positive titer during the gluten challenge, the
serum TG2 antibody levels tended to decrease even if glu-
ten consumption continued (Figure 5). Serum EMA and
DGP antibody titers were in line with TG2 antibody
results; furthermore, after the gluten challenge all these
Figure 1 Changes in small bowel mucosal villous height and
crypt depth ratios in moderate-dose group at baseline and at
completion of the study.
Figure 2 Changes in small bowel mucosal villous height and
crypt depth ratios in low-dose group at baseline and at
completion of the study.
Figure 3 Changes in small bowel mucosal densities of CD3+
IELs in moderate-dose group at baseline and at completion of
the study.
Figure 4 Changes in small bowel mucosal densities of CD3+ IELs
in low-dose group at baseline and at completion of the study.
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(data not shown). Small-bowel mucosal TG2-targeted
autoantibody deposits generally followed the gluten-
induced serological response in sera and morphological
changes seen in the biopsy specimens (Tables 2 and 3).
A tt h eo u t s e t ,a l ls u b j e c t sw e r ef r e eo fg a s t r o i n t e s t i n a l
symptoms. Altogether 15 (71%) out of the 21 celiac dis-
ease patients experienced mild to moderate abdominal
symptoms upon gluten challenge; eight of them (includ-
ing the four withdrawing prematurely, see above) were
from the moderate-dose and seven from the low-dose
group (Table 2). None developed severe symptoms. Thir-
teen (87%) out of the 15 symptomatic patients also devel-
oped small-intestinal mucosal changes (significant
decrease in Vh/CrD and/or increase in the density of
CD3+ IELs). Of note, symptoms did not reveal four celiac
disease patients having clinically significant gluten-
induced small-bowel mucosal damage.
Discussion
Twelve weeks’ gluten challenge with both moderate and
low amounts of gluten sufficed to induce small-bowel
mucosal morphological damage in the majority of
volunteer treated celiac disease adults not, however, in
all. An increase in the density of CD3+ IELs paralleled
this phenomenon especially in the moderate-dose gluten
challenge group. At the same time, moderate gluten
doses triggered more gastrointestinal symptoms leading
to premature withdrawals from the study. This suggests
that in the 12-week time-frame smaller gluten doses of
1-3 g per day might be preferable to higher doses in
order to obtain sufficient complete read-outs at the end
of a challenge study.
In this study, small-bowel mucosal Vh/CrD measure-
ment seemed to be the most sensitive parameter in both
moderate and low gluten doses in assessing gluten-
induced damage in celiac disease. This conception is also
in line with previous findings, where the Vh/CrD index
has been used to show harmful effects of gluten in both
short-term gluten challenges and long-term follow-up
studies [8,13,26,27]. It is not surprising that the IEL
count was a reliable marker for gluten toxicity only with
moderate, but not with low gluten doses, as it has pre-
viously been shown that in celiac disease during a gluten-
challenge, IELs accumulate in the surface and crypt
epithelium in a dose-dependent manner [3]. It is also
important to note that even if the majority of celiac dis-
ease patients after gluten challenge yielded positive read-
outs both in the Vh/CrD index and in the IEL count,
there were some discrepant cases responding only with
one or other parameter (Table 2). Marsh classification
entailing six diagnostic categories (type 0-type 3c) has
been widely used in the diagnostic work-up and follow-
up of celiac disease [3]. Marsh grades type 1-type 3c all
indicate cursorily that small-bowel mucosal IEL density
is increased (>40 IELs/100enterocytes), but different cate-
gories point more specifically to different morphological
features (such as normal villous morphology, crypt
hyperplasia or villous atrophy). Nonetheless the Marsh
classification does not take into account minor gluten-
induced mucosal changes (e.g. a significant decrease in
Vh/CrD or increase in density of IELs within one Marsh
grade) or discrepant results in Vh/CrD or IEL counts
during a gluten challenge. It would thus be advisable in
gluten challenge research projects, to use two separate
continuous readout parameters in assessing gluten-
dependent functional mucosal changes, i.e. the morpho-
logical Vh/CrD and the inflammatory IEL changes, as
opposed to applying a simplified grouped classification.
Even if abdominal symptoms after the consumption of
cereals do not generally constitute a specific marker of
untreated celiac disease [28], gluten-induced gastrointest-
inal symptoms in our challenge study showed high posi-
tive predictive value (87%) for small-bowel mucosal
injury in celiac disease patients. However, in 22% of the
cases who developed significant small-intestinal damage,
symptoms remained absent. It is widely known that
many untreated celiac disease patients do not suffer from
symptoms even if they have a manifest gluten-induced
small-bowel mucosal lesion [29]. Furthermore, in some
treated celiac disease patients, symptoms may disappear
on a strict gluten-free diet despite continued ongoing
mucosal villous atrophy [30,31]. Such persistent small-
intestinal villous atrophy in symptom-free patients clearly
carries a risk of subsequent severe complications such as
Figure 5 Changes in antibody levels. Transglutaminase 2 (TG2)
antibody levels at baseline, at 4 and 8 weeks, and at the end of the
study. Closed squares indicate moderate daily gluten dose 3-5 g
and open squares low gluten doses (1-3 g per day).
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tion in relying solely on symptoms or other patient-
related outcomes without small-bowel biopsies in gluten
challenge research projects.
In studies where a gluten challenge has been applied for
diagnostic purposes in children on a normal daily gluten-
containing diet (10-20 g daily), a small-bowel mucosal
histological relapse has usually developed within three to
twelve months in the majority of patients [8,9]. Serocon-
version of EMA and TG2 antibodies is known to be a reli-
able predictor of histological relapse and antibody testing
has helped in the timing of the biopsy [9]. In this study
with low to moderate gluten doses, only 43% of the chal-
lenged adult celiac disease patients evinced a significant
serological response. In line with earlier challenge studies,
here all those who had increased serum autoantibodies
during the challenge also developed small-bowel villous
atrophy. However, at the same time serology missed nine
cases with significant small-bowel mucosal changes
(Tables 2 and 3). These cases might have called for a
longer gluten challenge period or higher gluten amounts.
However, it is well-known that serology may fail to detect
occasional slight dietary transgressions and incomplete
mucosal healing [30,32,33], and therefore celiac serology is
not always a reliable means of assessing gluten-induced
harm. Furthermore, it is important to note that after the
gluten challenge all three antibody - EMA, TG2 and DPG
antibody - tests performed similar way, and recently intro-
duced DPG antibody test was not superior to conventional
serological assays. As small-bowel mucosal TG2-specific
autoantibody deposits have also been found in seronega-
tive celiac patients and patients with early-stage celiac dis-
ease [23,24,34], it has been hypothesized that these
mucosal autoantibodies might also appear early during a
gluten challenge. In our study, mucosal autoantibodies fol-
lowed the morphological damage, and they added only lit-
tle to the normal morphometrical measurements. It might
be that after a short-term acute gluten challenge the distri-
bution of mucosal autoantibody depositions is patchy, and
single mucosal biopsies may not reveal the positivity. It
remains to be seen whether they will be of use at earlier
time-points in the gluten challenge, but due to the invasive
nature of small-bowel biopsies we were not able to take
specimens on several occasions during the challenge.
There were some celiac disease patients who did not
respond in terms of any of the measured outcome vari-
ables during the 12 weeks’ gluten challenge. It is well-
known that celiac patients show varying sensitivity to
gluten and the process of mucosal deterioration may take
years or even decades [35-37]. Furthermore, it should be
remembered that the phenotype of the disease may vary
in the same person over time; celiac patients suffering
originally from abdominal symptoms at diagnosis may
later experience only extraintestinal symptoms such as
dermatitis herpetiformis wh e ng l u t e ni sr e - i n t r o d u c e d
into the diet [37]. These issues need to be taken into
account when sample sizes in study cohorts are
determined.
A tt h eb a s e l i n eo ft h es t u d y ,t h em a j o r i t yo ft h et r e a -
ted celiac disease patients evinced increased densities of
IELs and one patient even had villous atrophy with
crypt hyperplasia despite adherent to a strict long-term
gluten-free diet. According to the literature, such cases
exist and it has been shown that even 80% of treated
patients may have ongoing villous atrophy during a
strict diet [38-40]. These persistent mucosal changes
might be due to constant residual gluten contamination
in the food, which again would indicate that alternative
treatment options would be desirable.
Conclusions
All in all, further studies are still needed to establish the
optimal gluten dose on the other hand causing some
small-bowel mucosal deterioration but without inducing
excessive ill health. Our results suggest that in drug trials,
the duration of the gluten challenge might be shorter than
12 weeks and the gluten dose could be an average of those
used in the current study (approximately 3g). As there are
always some celiac disease patients who will not respond
within these conditions, sample sizes must be sufficiently
large to ensure adequate statistical power for the study.
The Vh/CrD index seemed to be the most reliable out-
come measurement in both moderate and low gluten
doses. Furthermore, it must be remembered that during a
gluten challenge, some celiac patients may remain asymp-
tomatic even if they develop manifest gluten-induced
mucosal damage - this might in the long-run predispose
these cases to celiac disease-related complications.
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